Immix Biopharma, Inc.

XNASHealth care

Last traded price · USD

$7.97

+3.37%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 03:44 IST · A quote does not mean the product is available to trade on your account.

Day's open: $7.93
Previous close: $7.71
Volume: 1.2M
Day's high: $8.16
Day's low: $7.56

In brief

Immix Biopharma, Inc. is a health care company listed on Nasdaq, valued at about $661M.
Its shares closed at $7.97 on 4 Nov 2026, up 139.3% over the past year.
From India you can buy IMMX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Immix Biopharma, Inc. (IMMX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole IMMX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade IMMX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −17.3% (SPY −1.6%, XLV +13.5%). 3 months: −16.5% (SPY −0.4%, XLV +15.5%). 1 year: +139.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IMMX, SPY and XLV · as of 4 Nov 2026
7.5 days to cover short interest
10.7M shares were sold short at the 15 Oct 2026 settlement, 15.0% of the 71.5M shares outstanding; covering them would take 7.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $7.97 was 25.1% below its 50-day average ($10.65) and 16.3% below its 200-day average ($9.53). It has closed below the 200-day for 18 sessions, since 12 Oct 2026. The 50-day average crossed above the 200-day on 2 Jun 2025, 359 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
42% of the way up its 52-week range
Closed at $7.97 on 4 Nov 2026: 47.2% below the 52-week high of $15.10 (25 Aug 2026) and 179.5% above the low of $2.85 (6 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−17.3%

6 months−22.8%

1 year+139.3%

5 years—

Newswire

About

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Website

Notable moves

December 14, 2023
+36.21%
December 9, 2022
+31.13%
January 3, 2022
+62.36%

Immix Biopharma, Inc.

XNASHealth care

Last traded price · USD

$7.97

+3.37%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 03:44 IST · A quote does not mean the product is available to trade on your account.

Day's open: $7.93
Previous close: $7.71
Volume: 1.2M
Day's high: $8.16
Day's low: $7.56

In brief

Immix Biopharma, Inc. is a health care company listed on Nasdaq, valued at about $661M.
Its shares closed at $7.97 on 4 Nov 2026, up 139.3% over the past year.
From India you can buy IMMX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Immix Biopharma, Inc. (IMMX) shares from India?

Do I need the price of a whole IMMX share to invest?

How much can I invest in US stocks in a year?

Can I trade IMMX options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −17.3% (SPY −1.6%, XLV +13.5%). 3 months: −16.5% (SPY −0.4%, XLV +15.5%). 1 year: +139.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IMMX, SPY and XLV · as of 4 Nov 2026
7.5 days to cover short interest
10.7M shares were sold short at the 15 Oct 2026 settlement, 15.0% of the 71.5M shares outstanding; covering them would take 7.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $7.97 was 25.1% below its 50-day average ($10.65) and 16.3% below its 200-day average ($9.53). It has closed below the 200-day for 18 sessions, since 12 Oct 2026. The 50-day average crossed above the 200-day on 2 Jun 2025, 359 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
42% of the way up its 52-week range
Closed at $7.97 on 4 Nov 2026: 47.2% below the 52-week high of $15.10 (25 Aug 2026) and 179.5% above the low of $2.85 (6 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−17.3%

6 months−22.8%

1 year+139.3%

5 years—

Newswire

About

Website

Notable moves

December 14, 2023
+36.21%
December 9, 2022
+31.13%
January 3, 2022
+62.36%

Immix Biopharma, Inc.

Immix Biopharma, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

7.5 days to cover short interest

Below its 50- and 200-day averages

42% of the way up its 52-week range

Immix Biopharma, Inc.

Immix Biopharma, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

7.5 days to cover short interest

Below its 50- and 200-day averages

42% of the way up its 52-week range